Skip to Main

Exclusive Financial Advisor to Global Nephrology Solutions

  • Oppenheimer & Co. Inc.
  • January 21, 2021
Oppenheimer Acted as Exclusive Financial Advisor to Global Nephrology Solutions on its Growth Investment from Audax Management Company

December 2020

Global Nephrology Solutions (“GNS”) announced a strategic growth investment from Audax Private Equity (“Audax”) to help expand the innovative, physician-led model shaping the future of renal care. GNS, with more than 300 providers and 500 employees supporting physicians who provide care across 10 states, is one of the nation’s leading physician-led nephrology organizations focused on the quadruple aim of improving outcomes, reducing the cost-of-care, and enhancing both patient and physician experience. GNS is transforming the kidney care space by leveraging next-generation data analytics, vast industry knowledge and experience, and cost-effective population health initiatives. Audax is a trusted private equity investor with a track record of success that includes over $6 billion in investments in more than 135 platform companies.

tombstone
For more information please contact:
Healthcare Investment Banking
Contact Info


Bailey Crespi
Business Development Associate
(305) 860-2656
bailey.crespi@opco.com

DISCLOSURES

This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2020 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC  3348103.1